[ back to News ]

Concert Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12

January 5, 2009

LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the 27th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, California.  Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Monday, January 12, 2009 at 2:00 p.m. (PT).

About Concert

Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium.  Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs).  By leveraging decades of pharmaceutical experience to design NCEs from proven therapies, Concert’s drug candidates have potential for first-in-class use in under-served medical conditions, as well as best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS, vasomotor symptoms, and renal disease, among others.  Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors.  A listing of Concert’s institutional shareholders and additional corporate information is available online at http://www.concertpharma.com.

CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]